Antiangiogenic Gene Therapy Added to Bevacizumab Leads to Better Overall Survival in Recurrent GBM

Press/Media: Press / Media

PeriodJul 13 2016

Media coverage

1

Media coverage

  • TitleAntiangiogenic Gene Therapy Added to Bevacizumab Leads to Better Overall Survival in Recurrent GBM
    Media name/outletTargeted Oncology
    CountryUnited States
    Date7/13/16
    PersonsAndrew Brenner